EMA's CHMP Recommends Not Granting Marketing Authorisation For Eli Lilly's Kisunla

Reuters

03-28

March 28 (Reuters) - EMA's CHMP: :
*EMA'S CHMP: RECOMMENDED NOT GRANTING MARKETING AUTHORISATION FOR KISUNLA (DONANEMAB)
*EMA'S CHMP: RECOMMENDED TO REFUSE EXTENDING MARKETING AUTHORISATION FOR PEMAZYRE (PEMIGATINIB)
*EMA'S CHMP:APPLICATION TO EXTEND USE OF AMYVID IN ADULTS TO MONITOR RESPONSE TO TREATMENTS THAT REDUCE BETA AMYLOID PLAQUES WAS WITHDRAWN
*EMA'S CHMP: FOR OPDIVO, RECOMMENDED A NEW PHARMACEUTICAL FORM AND NEW STRENGTH FOR SUBCUTANEOUS ADMINISTRATION
*EMA'S CHMP: CONCLUDED BENEFITS OF MYSIMBA CONTINUE TO OUTWEIGH ITS RISKS

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 28-MAR-202510:59:57 GMT

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2522522203"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522522203\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2522522203?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-28 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522522203","market":"nz","top_or_hot":-1,"title":"EMA's CHMP Recommends Not Granting Marketing Authorisation For Eli Lilly's Kisunla","media":"Reuters","content":"<html><body>March 28 (Reuters) - EMA's CHMP: :<br/>*EMA'S CHMP: RECOMMENDED NOT GRANTING  MARKETING AUTHORISATION FOR KISUNLA (DONANEMAB)<br/>*EMA'S CHMP: RECOMMENDED TO REFUSE EXTENDING MARKETING AUTHORISATION FOR PEMAZYRE (PEMIGATINIB)<br/>*EMA'S CHMP:APPLICATION TO EXTEND USE OF AMYVID IN ADULTS TO MONITOR RESPONSE TO TREATMENTS THAT REDUCE BETA AMYLOID PLAQUES WAS WITHDRAWN<br/>*EMA'S CHMP: FOR OPDIVO, RECOMMENDED A NEW PHARMACEUTICAL FORM AND NEW STRENGTH FOR SUBCUTANEOUS ADMINISTRATION<br/>*EMA'S CHMP: CONCLUDED BENEFITS OF MYSIMBA CONTINUE TO OUTWEIGH ITS RISKS<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 28-MAR-202510:59:57 GMT</body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EMA's CHMP Recommends Not Granting Marketing Authorisation For Eli Lilly's Kisunla</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEMA's CHMP Recommends Not Granting Marketing Authorisation For Eli Lilly's Kisunla\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-03-28 19:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body>March 28 (Reuters) - EMA's CHMP: :<br/>*EMA'S CHMP: RECOMMENDED NOT GRANTING  MARKETING AUTHORISATION FOR KISUNLA (DONANEMAB)<br/>*EMA'S CHMP: RECOMMENDED TO REFUSE EXTENDING MARKETING AUTHORISATION FOR PEMAZYRE (PEMIGATINIB)<br/>*EMA'S CHMP:APPLICATION TO EXTEND USE OF AMYVID IN ADULTS TO MONITOR RESPONSE TO TREATMENTS THAT REDUCE BETA AMYLOID PLAQUES WAS WITHDRAWN<br/>*EMA'S CHMP: FOR OPDIVO, RECOMMENDED A NEW PHARMACEUTICAL FORM AND NEW STRENGTH FOR SUBCUTANEOUS ADMINISTRATION<br/>*EMA'S CHMP: CONCLUDED BENEFITS OF MYSIMBA CONTINUE TO OUTWEIGH ITS RISKS<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 28-MAR-202510:59:57 GMT</body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0820561818.USD","symbol_name":"安聯收益及增長平衡基金Cl AM DIS","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nRSD3Xt4R8:1","article_id":"2522522203","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522522203","pubTimestamp":1743160225,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"March 28 (Reuters) - EMA's CHMP: :*EMA'S CHMP: RECOMMENDED NOT GRANTING  MARKETING AUTHORISATION FOR KISUNLA (DONANEMAB)*EMA'S CHMP: RECOMMENDED TO REFUSE EXTENDING MARKETING AUTHORISATION FOR PEMAZYR","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4588":"碎股","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999014906.USD":"大华全球优质成长基金Acc USD","SG9999001176.USD":"United Global Healthcare Acc USD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU0079474960.USD":"联博美国增长基金A","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LLY":"礼来","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","BK4516":"特朗普概念","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC"},"translate_title":"EMA的CHMP建议不授予礼来公司的Kisunla上市许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":0.9},"content_text":"March 28 (Reuters) - EMA's CHMP: :*EMA'S CHMP: RECOMMENDED NOT GRANTING  MARKETING AUTHORISATION FOR KISUNLA (DONANEMAB)*EMA'S CHMP: RECOMMENDED TO REFUSE EXTENDING MARKETING AUTHORISATION FOR PEMAZYRE (PEMIGATINIB)*EMA'S CHMP:APPLICATION TO EXTEND USE OF AMYVID IN ADULTS TO MONITOR RESPONSE TO TREATMENTS THAT REDUCE BETA AMYLOID PLAQUES WAS WITHDRAWN*EMA'S CHMP: FOR OPDIVO, RECOMMENDED A NEW PHARMACEUTICAL FORM AND NEW STRENGTH FOR SUBCUTANEOUS ADMINISTRATION*EMA'S CHMP: CONCLUDED BENEFITS OF MYSIMBA CONTINUE TO OUTWEIGH ITS RISKS  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 28-MAR-202510:59:57 GMT","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}